spacer
home > ebr > autumn 2009 > peptide potential
PUBLICATIONS
European Biopharmaceutical Review

Peptide Potential

 

Peptides, the most basic of building blocks in physiology, continue to grow in prominence among pharmaceutical manufacturers. With inherent abilities to block or enhance signal transfers in the human body, peptides, when harnessed as active pharmaceutical ingredients, can treat a host of metabolic diseases, cardiovascular and heart conditions, and neurodegenerative disorders.

Peptide-based drug targets are being identified at an increasingly rapid pace, both in terms of recently introduced therapies, and products in the development pipeline. In fact, a recent report by market and technology research firm Frost & Sullivan indicated that more than 40 approved peptide-based drugs are in use today, and approximately 400 are being developed to treat allergies, cancer, Alzheimer’s, Huntington’s and Parkinson’s diseases (1).

Peptide-based therapies tap into the direct hardwiring of human physiology, yielding substantial and far-reaching benefits to drug treatments and therapies. Moreover, developments in peptide manufacturing and implementation have made these amino acid compounds more accessible to the market in terms of cost, flexibility and effectiveness.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Hu oversees all non-GMP and GMP business divisions within the American Peptide Company (APC). He has been with APC for 18 years and he is tasked with keeping the organisation profitable and meeting growth objectives year after year. Gary spearheads the Total Peptide ManagementTM programme, a flagship initiative designed to help the pharmaceutical and life sciences industries bring new and innovative drugs to market faster. Specialising in business development, he emphasises a team approach to bring value and integrity to customers’ projects.
spacer
Gary Hu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Myeloma Patients Europe report finds huge inequalities in access to myeloma clinical trials in Central and Eastern Europe

Brussels, 30 November 2022 – Myeloma Patients Europe (MPE) has launched a first-of-its-kind advocacy report on Addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE)
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement